Lesinurad for the treatment of hyperuricaemia in people with gout.

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Robinson, Philip C en
dc.contributor.author Dalbeth, Nicola en
dc.date.accessioned 2018-11-18T23:33:02Z en
dc.date.issued 2017-12 en
dc.identifier.issn 1465-6566 en
dc.identifier.uri http://hdl.handle.net/2292/44417 en
dc.description.abstract Gout is a common form of inflammatory arthritis caused by deposition of monosodium urate crystals. The central strategy for effective long-term management of gout is serum urate lowering. Current urate-lowering drugs include both xanthine oxidase inhibitors and uricosuric agents. Lesinurad is a URAT1 inhibitor that selectively inhibits urate rebsorption at the proximal renal tubule. Lesinurad 200mg daily in combination with a xanthine oxidase is approved for urate-lowering therapy in patients with gout. Areas covered: The published literature was searched using Pubmed and additional information was obtained from publically available regulatory documents. Pre-clinical data and clinical trials of lesinurad are described. Serum urate-lowering efficacy and effects on other clinical endpoints are discussed. Adverse event data, focusing on renal safety are also presented. Expert opinion: Lesinurad is an effective urate-lowering drug that has a generally acceptable safety profile when used at 200mg daily dosing in combination with a xanthine oxidase inhibitor. The recent approval of fixed dose combination pills of lesinurad with allopurinol is an important step in improving adherence and reducing risk of renal adverse events. It remains to be seen if this therapy will provide additional benefit for gout management above improved use of widely available generic therapies. en
dc.format.medium Print-Electronic en
dc.language eng en
dc.relation.ispartofseries Expert opinion on pharmacotherapy en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Animals en
dc.subject Haplorhini en
dc.subject Humans en
dc.subject Gout en
dc.subject Hyperuricemia en
dc.subject Thioglycolates en
dc.subject Triazoles en
dc.subject Gout Suppressants en
dc.title Lesinurad for the treatment of hyperuricaemia in people with gout. en
dc.type Journal Article en
dc.identifier.doi 10.1080/14656566.2017.1401609 en
pubs.issue 17 en
pubs.begin-page 1875 en
pubs.volume 18 en
dc.rights.holder Copyright: The author en
dc.identifier.pmid 29103339 en
pubs.end-page 1881 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Clinical Trial, Phase III en
pubs.subtype Clinical Trial, Phase II en
pubs.subtype Clinical Trial, Phase I en
pubs.subtype Journal Article en
pubs.elements-id 711138 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Medicine Department en
dc.identifier.eissn 1744-7666 en
pubs.record-created-at-source-date 2017-11-07 en
pubs.dimensions-id 29103339 en

Full text options

Full text for this item is not available in ResearchSpace.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace

Advanced Search